EMS Slashes Ozivy Price for Diabetes Treatment in Discount Program
Brazilian pharmaceutical company EMS has announced new discount conditions for its semaglutide medication, Ozivy, used to treat type 2 diabetes. Under a revised loyalty program, patients can now purchase three 1 mg pens for approximately R$ 999, bringing the cost per pen down to around R$ 333. This represents a significant price reduction compared to the previous offering of two 1 mg pens for R$ 863.22, which remains available. To qualify for these discounted prices, patients must register for the program and present a valid medical prescription at participating pharmacies. The company's strategy with Ozivy, launched this year as a domestic alternative to Novo Nordisk's Ozempic following patent expiry, has focused on competitive pricing and patient discount programs. Ozivy, produced through chemical synthesis, received Anvisa registration in May and is specifically indicated for type 2 diabetes management. The program, called Vida + Leve, allows registration via its website or at accredited pharmacies with a valid prescription.
This pricing adjustment by EMS reflects a strategic market entry following the expiry of Novo Nordisk's patent on semaglutide. By offering a lower-cost domestic alternative, EMS aims to capture market share in the growing diabetes treatment sector. The discount program incentivizes patient adherence and brand loyalty, particularly important for chronic conditions requiring long-term medication. This competitive pricing dynamic, driven by the introduction of generics and biosimilars, is a common market evolution that can increase accessibility for patients. It highlights the interplay between patent law, pharmaceutical innovation, and public health outcomes, as lower prices can expand treatment reach. Future market developments may involve further price competition and innovation in drug delivery systems or combination therapies.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.